Literature DB >> 3702024

Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness.

M B Keller, P W Lavori, W Coryell, N C Andreasen, J Endicott, P J Clayton, G L Klerman, R M Hirschfeld.   

Abstract

We found significant differences in time to recovery and rates of chronicity in 155 patients with bipolar illness when the episodes were subtyped into those with manic symptoms alone (pure manic), depressive symptoms alone (pure depressed), or symptoms of depression and mania (mixed or cycling) up to the time of entry into a clinical research study. Most of the patients in all three groups who did not recover received levels of somatotherapy that were generally consistent with current recommendations for intensity of treatment appropriate to each condition. Based on a median follow-up of 18 months, the life-table estimate of the probability of remaining ill for at least one year was 7% for the pure manic patients compared with 32% in patients who entered the study with episodes that were mixed or cycling. Purely depressed patients had a 22% probability of remaining ill, approximating rates found in patients without bipolar illness who have episodes of depression. Different clinical variables were found to predict time to recovery in each of these groups. We propose that this subtyping of episodes may be a clinically useful part of the classification of bipolar disorders.

Entities:  

Mesh:

Year:  1986        PMID: 3702024

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  36 in total

Review 1.  Functional impairment and cognition in bipolar disorder.

Authors:  C A Zarate; M Tohen; M Land; S Cavanagh
Journal:  Psychiatr Q       Date:  2000

Review 2.  Bipolar depression: management options.

Authors:  Gin S Malhi; Philip B Mitchell; Shahzad Salim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Prevalence and clinical significance of subsyndromal manic symptoms, including irritability and psychomotor agitation, during bipolar major depressive episodes.

Authors:  Lewis L Judd; Pamela J Schettler; Hagop Akiskal; William Coryell; Jan Fawcett; Jess G Fiedorowicz; David A Solomon; Martin B Keller
Journal:  J Affect Disord       Date:  2012-02-06       Impact factor: 4.839

4.  A New Option for Treating Bipolar I Depression.

Authors:  Holly A Swartz; Joseph T Tasosa
Journal:  Am J Psychiatry       Date:  2016-03-01       Impact factor: 18.112

5.  The pharmacogenetics of lithium response depends upon clinical co-morbidity.

Authors:  Troy Bremer; Cornelius Diamond; Rebecca McKinney; Tatyana Shehktman; Thomas B Barrett; Chris Herold; John R Kelsoe
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

6.  Treatment of bipolar mixed state with olanzapine.

Authors:  V Sharma; L Pistor
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

7.  Early improvement with lithium in classic mania and its association with later response.

Authors:  Rodrigo Machado-Vieira; David A Luckenbaugh; Marcio G Soeiro-de-Souza; Getulio Marca; Ioline D Henter; Joao V Busnello; Wagner F Gattaz; Carlos A Zarate
Journal:  J Affect Disord       Date:  2012-08-17       Impact factor: 4.839

8.  Course and outcome of acute non-organic psychotic states in India.

Authors:  V K Varma; S Malhotra; E S Yoo; R C Jiloha; M T Finnerty; E Susser
Journal:  Psychiatr Q       Date:  1996

9.  Empirical typology of bipolar I mood episodes.

Authors:  David A Solomon; Andrew C Leon; Jean Endicott; William H Coryell; Chunshan Li; Jess G Fiedorowicz; Martin B Keller
Journal:  Br J Psychiatry       Date:  2009-12       Impact factor: 9.319

10.  Excessive substance use in bipolar disorder is associated with impaired functioning rather than clinical characteristics, a descriptive study.

Authors:  Trine V Lagerberg; Ole A Andreassen; Petter A Ringen; Akiah O Berg; Sara Larsson; Ingrid Agartz; Kjetil Sundet; Ingrid Melle
Journal:  BMC Psychiatry       Date:  2010-01-27       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.